Long‐term safety of growth hormone—A combined registry analysis
The DOI matches its Crossref record; 11 of the 11 references it cites were found in a registry or an index.
Abstract
Summary: Objectives: Preliminary data from the French cohort of the Safety and Appropriateness of Growth hormone treatments in Europe (SAG hE) study raised concerns regarding the safety of recombinant human GH, suggesting that GH may increase mortality and incidence of stroke in patients treated during childhood for GH deficiency or short stature. We evaluated published safety data, focusing on mortality, neoplasms, cerebrovascular events and diabetes across a number of large‐scale pharmaceutical company GH registries. Design: A literature review was conducted using PubMed, EMBASE and Google Scholar to identify all relevant safety data from manufacturers' GH registries published between 1988 and April 2016. Results were hand‐sorted to exclude nonrelevant publications; bibliographic references from retrieved articles were evaluated for any additional references. Results: The published data do not support an increased risk of mortality in children or adults treated with GH. There was no evidence of an increased risk of stroke, new malignancy, leukaemia, nonleukaemic extracranial tumours or recurrence of intracranial malignancy in patients without risk factors. The risk of a second neoplasm is increased, particularly if patients have received radiation therapy for a central nervous system tumour. There may be an increased risk of type 2 diabetes in GH‐treated patients, but this appears to be confined to those with pre‐existing risk factors. Conclusions: Patients with risk factors for malignancy or type 2 diabetes should be treated with caution and monitored during follow‐up, but current published data provide reassurance on the long‐term safety profile of GH in patients receiving GH treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Increased cerebrovascular mortality in patients with hypopituitarism
Bülow, B., Hagmar, L., Mikoczy, Z., Nordström, C., & Erfurth, E. M. (1997) · Clinical Endocrinology · doi:10.1046/j.1365-2265.1997.d01-1749.x · Cited by 542
Cutfield, W. S., Wilton, P., Bennmarker, H., Albertsson-Wikland, K., Chatelain, P., Ranke, M. B., & Price, D. A. (2000) · The Lancet · doi:10.1016/s0140-6736(99)04055-6 · Cited by 318
Long-term safety of recombinant human growth hormone in children
Bell, J., Parker, K. L., Swinford, R. D., Hoffman, A. R., Maneatis, T., & Lippe, B. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-0178 · Cited by 301
Blethen, S. L., Allen, D. B., Graves, D., August, G., Moshang, T., & Rosenfeld, R. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.5.8626820 · Cited by 246
Changes in incidence of diabetes in U.S. adults, 1997–2003
Geiss, L. S., Pan, L., Cadwell, B., Gregg, E. W., Benjamin, S. M., & Engelgau, M. M. (2006) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2005.12.009 · Cited by 229
Adult growth hormone deficiency - benefits, side effects, and risks of growth hormone replacement
Reed, M. L., Merriam, G. R., & Kargi, A. Y. (2013) · Frontiers in Endocrinology · doi:10.3389/fendo.2013.00064 · Cited by 119
Attanasio, A. F., Mo, D., Erfurth, E. M., Tan, M., Ho, K. Y., Kleinberg, D., Zimmermann, A. G., & Chanson, P. (2010) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2009-1326 · Cited by 115
The cardiovascular system in growth hormone excess and growth hormone deficiency.
(2012) · PubMed · doi:10.3275/8717 · Cited by 80
Child, C. J., Zimmermann, A. G., Scott, R. S., Cutler, G. B., Battelino, T., & Blum, W. F. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-3023 · Cited by 71
Child, C. J., Conroy, D., Zimmermann, A. G., Woodmansee, W. W., Erfurth, E. M., & Robison, L. L. (2015) · European Journal of Endocrinology · doi:10.1530/eje-14-1123 · Cited by 58
Cited by
Yuen, K. C. J., Biller, B. M. K., Radovick, S., Carmichael, J. D., Jasim, S., Pantalone, K. M., & Hoffman, A. R. (2019) · Endocrine Practice · doi:10.4158/gl-2019-0405 · Cited by 298
Clinical practice guidelines for the care of girls and women with Turner syndrome.
Gravholt, C. H., Andersen, N. H., Christin-Maitre, S., Davis, S. M., Duijnhouwer, A., Gawlik, A., Maciel-Guerra, A. T., Gutmark-Little, I., Fleischer, K., Hong, D., et al. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae050 · Cited by 224
Self-citationSafety and efficacy of pediatric growth hormone therapy: results from the full KIGS cohort
Maghnie, M., Ranke, M. B., Geffner, M. E., Vlachopapadopoulou, E., Ibáñez, L., Carlsson, M., Cutfield, W., Rooman, R., Gomez, R., Wajnrajch, M. P., et al. (2022) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgac517 · Cited by 120
Child, C. J., Zimmermann, A. G., Chrousos, G. P., Cummings, E., Deal, C. L., Hasegawa, T., Jia, N., Lawrence, S., Linglart, A., Loche, S., et al. (2019) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2018-01189 · Cited by 80
Backeljauw, P., Blair, J. C., Ferran, J.-M., Kelepouris, N., Miller, B. S., Pietropoli, A., Polak, M., Sävendahl, L., Verlinde, F., & Rohrer, T. R. (2023) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgad159 · Cited by 12
Metadata
- Authors
- Stochholm, K., & Kiess, W.
- Venue
- Clinical Endocrinology
- Publisher
- Wiley
- Published
- 2017-11-20
- Volume
- 88
- Issue
- 4
- Pages
- 515-528
- ISSN
- 0300-0664 (ISSN-L)
- 1365-2265
- OpenAlex
- W2765522237
- Cited by
- 74
- References
- 11
- FWCI
- 5.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long‐term safety of growth hormone—A combined registry analysis. https://app.cochat.ai/papers/10.1111/cen.13502
- The paper
- Stochholm, K., & Kiess, W. (2018). Long‐term safety of growth hormone—A combined registry analysis. Clinical Endocrinology. https://doi.org/10.1111/cen.13502
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.